ERBB2 and breast cancer: TAILORx demonstrated that women with HR+, HER2−, N0, early BC would not benefit from CT if 1) they have an RS ≤ 16 regardless of age or 2) have an RS ≤ 25 and are aged 50 or more (10, 17).